New York, NY (PRWEB) April 17, 2014
The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services – announced today the publication of its Recent Advances in Mantle Cell Lymphoma: Report of the 2013 Mantle Cell Lymphoma Consortium Workshop in the journal, Leukemia & Lymphoma.
The world’s leading mantle cell lymphoma researchers convened at the Lymphoma Research Foundation’s 10th Annual Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop in Atlanta, GA on April 24-25, 2013 to report on the latest research findings and exchange ideas on how to improve treatment options for people living with mantle cell lymphoma. Key topics discussed at the Mantle Cell Lymphoma Consortium Scientific Workshop included new findings regarding the biology of MCL, novel potential targets for MCL therapy, and results of recent and ongoing clinical trials in MCL. This year’s meeting also featured a debate in which several researchers at the forefront of MCL treatment discussed how to best use stem cell transplantation in mantle cell lymphoma.
“The Lymphoma Research Foundation’s Mantle Cell Lymphoma Consortium provides a unique forum for the world’s leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations,” said Elizabeth Thompson, Chief Executive Officer of the Lymphoma Research Foundation. “Since its inception ten years ago, the MCLC Scientific Workshop has helped researchers make significant strides in understanding MCL biology, evaluating potential new therapies, and optimizing the use of currently available therapies; the Foundation is proud to convene this annual meeting so that advances in MCL can be accelerated.”
Highlights from LRF’s 2013 Mantle Cell Lymphoma Consortium Scientific Workshop have been published in Leukemia & Lymphoma. The authors of the report are members of the Foundation’s MCLC Executive Committee and include: Leo Gordon, MD, Northwestern University Feinberg School of Medicine (Chair); Steven Bernstein, MD, University of Rochester Medical Center; Pedro Jares, PhD, IDIBAPS, University of Barcelona; Brad Kahl, MD, University of Wisconsin, UW Carbone Cancer Center; Thomas Witzig, MD, Mayo Clinic; and Martin Dreyling, MD, PhD, University of Munich-Grosshadern. Traditionally accessible only to subscribers, Leukemia & Lymphoma is making this report available to the public for one month. To read the entire report, visit: http://informahealthcare.com/doi/abs/10.3109/10428194.2013.876634.
Mantle cell lymphoma (MCL) is a rare and often aggressive form of non-Hodgkin lymphoma (NHL), constituting about six percent of all NHL cases in the United States (more than 4,000 cases per year). In an effort to accelerate advances in the field of MCL, the Lymphoma Research Foundation established the Mantle Cell Lymphoma Consortium (MCLC) in 2003. To learn more about lymphoma or mantle cell lymphoma, visit lymphoma.org.
About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded more than $54 million in lymphoma-specific research.
For additional information on LRF’s research, education and services, visit lymphoma.org
About Leukemia & Lymphoma
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. The Journal is also dedicated to education in the form of reviews, commentaries, conference summaries and emerging drug profiles.
Leukemia & Lymphoma provides a premier reference source for physicians and scientists interested in clinical, translational, and laboratory research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders.
Visit the Journal’s homepage at http://informahealthcare.com/lal.